UNITED GUARDIAN INC 10-Q

ug20260630_10q.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 1-10526 UNITED-GUARDIAN, INC. . (Exact Name of Registrant as Specified in Its Charter) Delaware 11-1719724 (State or Other Jurisdiction of (I.R.S. Employer Identification No.) Incorporation or Organization) 230 Marcus Boulevard , Hauppauge , New York 11788 (Address of Principal Executive Offices) ( 631 ) 273-0900 (Registrant ’ s Telephone Number) N/A (Former name, former address, and former fiscal year, if changed since last report) Cover Page 1 of 2 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.10 par value per share UG NASDAQ Global Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( § 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “ large accelerated filer ” , “ accelerated filer ” , “ smaller reporting company ” , and “ emerging growth company ” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☑ Smaller reporting company ☑ Emerging growth company ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☑ Indicate the number of shares outstanding of each of the issuer ’ s classes of common stock, as of the latest practicable date: As of August 3, 2026, the Registrant had issued and outstanding 4,594,319 shares of Common Stock, $.10 par value per share ("Common Stock"). Cover Page 2 of 2 UNITED-GUARDIAN, INC. INDEX TO FINANCIAL STATEMENTS Page No. Part I. FINANCIAL INFORMATION Item 1 - Condensed Financial Statements (unaudited unless indicated otherwise) 2 Statements of Income - Three and Six Months ended June 30, 2026 and 2025 2 Balance Sheets – June 30, 2026 (unaudited) and December 31, 2025 (audited) 3 - 4 Statements of Changes in Stockholders’ Equity – Three and Six Months ended June 30, 2026 and 2025 5 Statements of Cash Flows – Six Months ended June 30, 2026 and 2025 6 Notes to Condensed Financial Statements 7 - 16 Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 17 - 21 Item 3 - Quantitative and Qualitative Disclosures About Market Risk 21 Item 4 - Controls and Procedures 21 Part II. OTHER INFORMATION Item 1 - Legal Proceedings 21 Item 1A - Risk Factors 21 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3 - Defaults Upon Senior Securities 22 Item 4 - Mine Safety Disclosures 22 Item 5 - Other Information 22 Item 6 - Exhibits 22 Signatures 23 1 of 23 UNITED-GUARDIAN, INC. Part I. FINANCIAL INFORMATION ITEM 1. Condensed Financial Statements STATEMENTS OF INCOME (unaudited) THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2026 2025 2026 2025 Net sales $ 3,108,267 $ 2,838,225 $ 5,980,489 $ 5,319,352 Costs and expenses: Cost of sales 1,562,465 1,340,854 3,010,254 2,463,930 Operating expenses 667,282 694,050 1,334,245 1,326,785 Research and development expense 124,395 107,868 239,416 222,262 Total costs and expenses 2,354,142 2,142,772 4,583,915 4,012,977 Income from operations 754,125 695,453 1,396,574 1,306,375 Other income: Investment income 70,445 70,573 140,259 155,260 Net gain on marketable securities 48,365 24,576 66,107 36,926 Settlement income 36,360 --- 339,493 --- Gain on sale of asset 8,310 --- 8,310 --- Total other income 163,480 95,149 554,169 192,186 Income before provision for income taxes 917,605 790,602 1,950,743 1,498,561 Provision for income taxes 189,026 163,776 403,262 310,840 Net income $ 728,579 $ 626,826 $ 1,547,481 $ 1,187,721 Earnings per common share (basic and diluted) $ 0.16 $ 0.14 $ 0.34 $ 0.26 Weighted average shares (basic and diluted) 4,594,319 4,594,319 4,594,319 4,594,319 See Notes to Condensed Financial Statements 2 of 23 UNITED-GUARDIAN, INC. BALANCE SHEETS JUNE 30, DECEMBER 31, 2026 2025 (unaudited) (audited) Current assets: Cash and cash equivalents $ 2,390,738 $ 1,251,097 Marketable securities 7,203,057 7,322,646 Accounts receivable, net of allowance for credit losses of $ 21,270 at June 30, 2026 and $ 17,169 at December 31, 2025 1,690,819 1,586,889 Inventories, net 1,179,450 1,507,763 Prepaid expenses and other current assets 210,884 207,839 Prepaid income taxes 39,819 325,163 Total current assets 12,714,767 12,201,397 Net property, plant, and equipment : Land 69,000 69,000 Factory equipment and fixtures 4,778,413 4,786,309 Building and improvements 3,365,326 3,352,276 Total property, plant, and equipment 8,212,739 8,207,585 Less: Accumulated depreciation 7,334,927 7,300,403 Total property, plant, and equipment, net 877,812 907,182 TOTAL ASSETS $ 13,592,579 $ 13,108,579 See Notes to Condensed Financial Statements 3 of 23 UNITED-GUARDIAN, INC. BALANCE SHEETS (continued) LIABILITIES AND STOCKHOLDERS ’ EQUITY JUNE 30, DECEMBER 31, 2026 2025 (unaudited) (audited) Current liabilities: Accounts payable $ 499,754 $ 480,791 Accrued expenses and other current liabilities 1,219,333 1,164,948 Deferred revenue 8,135 12,177 Dividends payable 10,093 11,405 Total current liabilities 1,737,315 1,669,321 Deferred income taxes, net 224,351 207,246 Total liabilities $ 1,961,666 $ 1,876,567 Commitments and contingencies Stockholders ’ equity: Common stock $ .10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at June 30, 2026 and December 31, 2025 459,432 459,432 Retained earnings 11,171,481 10,772,580 Total stockholders ’ equity 11,630,913 11,232,012 TOTAL LIABILITIES AND STOCKHOLDERS ’ EQUITY $ 13,592,579 $ 13,108,579 See Notes to Condensed Financial Statements 4 of 23 UNITED-GUARDIAN, INC. STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) THREE AND SIX MONTHS ENDED JUNE 30, 2026 Common stock Retained Shares Amount Earnings Total Balance, January 1, 2026 4,594,319 $ 459,432 $ 10,772,580 $ 11,232,012 Net income --- --- 818,902 818,902 Dividends declared and paid ($ 0.25 per share) --- --- ( 1,148,536 ) ( 1,148,536 ) Dividends declared but not paid ($ 0.25 per share) --- --- ( 44 ) ( 44 ) Balance, March 31, 2026 4,594,319 $ 459,432 $ 10,442,902 $ 10,902,334 Net income --- --- 728,579 728,579 Balance, June 30, 2026 4,594,319 $ 459,432 $ 11,171,481 $ 11,630,913 THREE AND SIX MONTHS ENDED JUNE 30, 2025 Common stock Retained Shares Amount Earnings Total Balance, January 1, 2025 4,594,319 $ 459,432 $ 11,423,434 $ 11,882,866 Net income --- --- 560,895 560,895 Dividends declared and paid ($ 0.35 per share) ( 1,607,893 ) ( 1,607,893 ) Dividends declared but not paid ($ 0.35 per share) --- ---- ( 119 ) ( 119 ) Balance, March 31, 2025 4,594,319 $ 459,432 $ 10,376,317 $ 10,835,749 Net income --- --- 626,826 626,826 Balance, June 30, 2025 4,594,319 $ 459,432 $ 11,003,143 $ 11,462,575 See Notes to Condensed Financial Statements 5 of 23 UNITED-GUARDIAN, INC. STATEMENTS OF CASH FLOWS (unaudited) SIX MONTHS ENDED June 30, 2026 2025 Cash flows from operating activities: Net income $ 1,547,481 $ 1,187,721 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 58,374 50,184 Net gain on marketable securities ( 66,107 ) ( 36,926 ) Gain on sale of asset ( 8,310 ) --- Allowance for credit losses 4,101 7,286 Change in allowance for obsolete inventory ( 8,000 ) ( 2,786 ) Deferred income taxes 17,105 253,703 (Increase) decrease in operating assets: Accounts receivable ( 108,031 ) ( 486,325 ) Inventories 336,313 ( 77,036 ) Prepaid expenses and other current assets ( 3,045 ) ( 26,028 ) Prepaid income taxes 285,344 ( 193,643 ) Increase (decrease) in operating liabilities: Accounts payable 18,963 ( 9,395 ) Accrued expenses 54,385 ( 170,064 ) Deferred revenue ( 4,042 ) 128,632 Net cash provided by operating activities 2,124,531 625,323 Cash flows from investing activities: Acquisition of property, plant, and equipment ( 29,004 ) ( 21,221 ) Proceeds from sale of asset 8,310 --- Proceeds from sale of marketable securities 6,673,508 7,301,264 Purchase of marketable securities ( 6,487,812 ) ( 6,394,357 ) Net cash provided by investing activities 165,002 885,686 Cash flows from financing activities: Dividends paid ( 1,149,892 ) ( 1,618,183 ) Net cash used in financing activities ( 1,149,892 ) ( 1,618,183 ) Net increase (decrease) in cash and cash equivalents 1,139,641 ( 107,174 ) Cash and cash equivalents at beginning of period 1,251,097 1,875,655 Cash and cash equivalents at end of period $ 2,390,738 $ 1,768,481 Supplemental disclosure of cash flow information Taxes paid $ 100,813 $ 250,780 Supplemental disclosure of non-cash items: Dividends payable $ 44 $ 119 See Notes to Condensed Financial Statements 6 of 23 UNITED-GUARDIAN, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (unaudited) 1. Business United-Guardian, Inc. (“Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. The Company conducts various research and development (“R&D”) activities. The Company’s R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. The R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets in which our products are used. All the products that the Company markets, except for Renacidin ® , are produced at our facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for us by an outside contract manufacturer. 2. Basis of Presentation Interim condensed financial statements of the Company are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and six months ended June 30, 2026 (also referred to as the "second quarter of 2026" and the "first half of 2026", respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2026. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. 3. Segment Information The Company operates its business under one operating segment, which is also its reportable segment. The Company's chief operating decision maker (“CODM”), who is the President, reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with our Board of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in our best interest and the best interest of our stockholders. Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income. 4. Macroeconomic and Geopolitical Conditions Recent and ongoing geopolitical tensions and conflicts in key oil- and gas-producing regions, including Iran, Venezuela, the Middle East, and Eastern Europe, have created significant uncertainty and volatility in global energy markets. The immediate impact on the Company has primarily been related to an increase in freight costs and certain raw materials that are dependent on the petrochemical industry. The availability and cost of direct materials, including raw materials and packaging materials, are critical to our operations. As oil prices rise, our customers may also decide to adjust demand forecasts to manage rising costs. Our business, financial condition and results of operations could be adversely affected by developments in these regions. 7 of 23 In addition, during 2025, the United States (“U.S.”) changed its long-standing trade policies and announced significant new tariffs, with certain exceptions, on virtually all imported goods. These actions triggered the negotiation of new trade agreements with certain U.S. trading partners. While these negotiations resulted in the reduction of certain recently imposed tariffs, the average U.S. tariff rate remains at its highest level since the 1930s. In response to the changes in U.S. trade policies, certain U.S. trading partners imposed retaliatory tariffs on U.S. imports. Shifts in tariffs, trade agreements, import/export restrictions, trade sanctions, sector specific trade barriers, and other governmental trade actions, whether enacted by the U.S. or other countries, especially those instituted in the Company's significant markets or markets where its significant customers are located and the associated uncertainty of long-term trade policies, could impact the Company's sales volume, sales prices, and other costs. Changes in trade policies may also cause disruptions to material sourcing and availability, global supply chains and logistics and access to end markets. Additionally, changes in U.S. trade policy and associated responses from trading partners may create shifts in global market dynamics and result in continued global financial market volatility. The impact of these changes in trade policies and the resulting trade and market uncertainty could have a negative impact on the Company’s results of operations. There can be no assurance that in the future, the U.S. or other countries or international trade bodies will not institute new tariffs or more restrictive trade policies or remedies and, as a result, the Company may face additional uncertainty and adverse impact on its business, financial condition and results of operations. 5. Use of Estimates In preparing financial statements in conformity with Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead. 6. Cash and Cash Equivalents For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of the maturities of United States Treasury Bills. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At June 30, 2026 and December 31, 2025, approximately $ 388,000 and $ 1,300 , respectively, exceeded the FDIC limit. The Company also invests in certain money market mutual funds that are protected as securities by the Securities Investor Protection Corporation (“SIPC”). At June 30, 2026 and December 31, 2025, cash held in these money market mutual funds of approximately $ 1,337,000 and $ 502,000 , respectively, exceeded the SIPC limit. The following table summarizes the Company's cash and cash equivalents: June 30, December 31, 2026 2025 Demand Deposits $ 553,622 $ 248,997 Money Market Funds 1,837,116 1,002,100 Total Cash and Cash Equivalents $ 2,390,738 $ 1,251,097 8 of 23 7. Accounts Receivable and Reserves The Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions. The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At June 30, 2026 and December 31, 2025 the allowance for credit losses related to accounts receivable amounted to $ 21,270 and $ 17,169 , respectively. 8. Revenue Recognition The Company records revenue in accordance with ASC Topic 606 “ Revenue from Contracts with Customers .” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. Our principal source of revenue is product sales. Our sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of our pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with our current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period. During 2026 and 2025, we participated in various government drug rebate programs related to the sale of Renacidin, our most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Manufacturer Discount Program (“MDP”) (formerly the Medicare Part D Coverage Gap Discount Program (“CGDP”)). These programs require us to sell our product at a discounted price, typically given in the form of a rebate. Our sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized. On January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but it is expected to increase Medicare Part D rebates for drug manufacturers. The Company’s status as a “specified small manufacturer” by CMS, entitles us to a multi-year phase-in period during which we would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on our current level of sales through the Medicare Part D Program, we would have reduced rebate liabilities beginning in 2025, with rebates gradually increasing each year thereafter, until they reach their full phase-in by 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to exceed the liabilities we have recorded under the CGDP in previous years. 9 of 23 As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, we recognize revenue from sales of most of our products when those products are shipped, which is when our performance obligation is satisfied. Our cosmetic, sexual wellness, and medical products are shipped EXW from our facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of our medical lubricant products are deemed final upon shipment, and we have no obligation to repurchase or allow the return of these goods unless they are defective. We consider sales of our pharmaceutical products to be final upon shipment unless (a) they are found to be defective; (b) the product is damaged or lost during shipping; (c) the product is too close to its expiration date for the customer to sell; or (d) the product is expired but is not more than one year after its expiration date. These return policies are in conformance with standard pharmaceutical industry practice. We estimate an allowance for outdated material returns based on previous years’ historical returns of our pharmaceutical products. The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of our products is not contingent upon the customer being able to sell the goods to a third party. Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At June 30, 2026 and December 31, 2025, the Company had allowances of $ 202,222 and $ 194,947 , respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed. We have not experienced significant fluctuations between estimated allowances and actual activity. At June 30, 2026, the Company recorded advance payments from customers of $ 8,135 , which are included in deferred revenue on the balance sheet. The related performance obligations associated with these payments are expected to be satisfied in the third quarter of 2026. At December 31, 2025, the Company recorded advance payments from customers of $ 12,177 . The related performance obligations associated with these payments were satisfied in the first quarter of 2026. The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitle them to distribution and service-related fees. The Company records distribution fees and estimates of distribution fees as offsets to revenue. Disaggregated sales by product class are as follows: Three months ended Six months ended June 30, June 30, 2026 2025 2026 2025 Pharmaceuticals $ 1,468,342 $ 1,451,679 $ 2,912,310 $ 2,620,137 Cosmetic & Sexual Wellness ingredients 1,286,699 896,549 2,131,963 1,595,546 Medical lubricants 353,226 489,997 936,216 1,103,669 Total Net Sales $ 3,108,267 $ 2,838,225 $ 5,980,489 $ 5,319,352 The Company’s pharmaceutical products are marketed primarily by three of the largest U.S. pharmaceutical wholesalers. The Company’s cosmetic ingredients are marketed worldwide by five distributors, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. The Company’s sexual wellness ingredients are marketed by two distributors, one that distributes the Company’s products in the United States, Canada, Mexico and France and another that distributes in the UK. For both three-month periods ended June 30, 2026 and 2025, approximately 17 % of the Company’s total sales were to customers located outside of the United States. For the six months ended June 30, 2026, approximately 20 % of the Company’s total sales were to customers located outside of the United States, compared with approximately 23 % for the six months ended June 30, 2025. 10 of 23 Disaggregated sales by geographic region are as follows: Three months ended Six months ended June 30, June 30, 2026 2025 2026 2025 United States* $ 2,573,234 $ 2,346,526 $ 4,808,126 $ 4,103,793 Other countries 535,033 491,699 1,172,363 1,215,559 Total Sales $ 3,108,267 $ 2,838,225 $ 5,980,489 $ 5,319,352 * Since all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 72 % of its sales of the Company’s products in the second quarter of 2026 were to foreign customers, with China representing approximately 39 %. For the same time period in 2025, approximately 80 % of ASI’s sales of the Company’s products were to foreign customers, with China representing approximately 42 %. For the six months ended June 30, 2026, approximately 72 % of ASI’s sales of the Company’s products were to customers in other countries, with China accounting for approximately 38 % of ASI’s sales of the Company’s products, as compared with approximately 75 % of ASI’s sales going to customers in other countries for the six months ended June 30, 2025, with China accounting for approximately 40 % of ASI’s sales of the Company’s products during that period. 9. Accounting for Financial Instruments – Credit Losses The Company recognizes an allowance for trade receivables to present the net amount expected to be collected as of the balance sheet date in accordance with ASU 2025-05. In July 2025, the Financial Accounting Standard Board (“FASB”) issued ASU 2025-05, which provides (1) all entities with a practical expedient and (2) entities other than public business entities with an accounting policy election when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, Revenue from Contracts with Customers. The practical expedient allows an entity to assume that, when estimating expected credit losses, current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. The Company adopted ASU 2025-05 for the year ended December 31, 2025. The adoption did not have a material impact on its financial condition, results of operations or cash flows. The Company performs ongoing credit evaluations of its customers and adjust credit limits, as determined by a review of current credit information. In addition, the Company continuously monitors collection and payments from customers and maintains an allowance for credit losses based upon historical experience, anticipation of uncollectible accounts receivable and any specific customer collection issues that have been identified. While the Company’s credit losses have historically been low and within expectations, we may not experience the same credit loss rates that have historically been attained in the future. The receivables are highly concentrated in a relatively small number of customers. Therefore, a significant change in the liquidity, financial position, or willingness to pay timely, or at all, of any one of our significant customers would have a significant impact on our results of operations and cash flows. The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken. 11 of 23 10. Marketable Securities The Company’s marketable securities include investments in equity mutual funds and United States Treasury Bills (“U.S. Treasury Bills”) with maturities longer than 3 months. Our marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. We evaluate our investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and our ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The disaggregated net gains and losses on marketable securities that were recognized on the income statements for the three and six months ended June 30, 2026 and 2025 were as follows: THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2026 2025 2026 2025 Net gains recognized during the period on marketable securities $ 48,365 $ 24,576 $ 66,107 $ 36,926 Less: Net (gains) losses recognized on marketable securities sold during the period --- --- ( 27,948 ) 1,507 Net unrealized gains recognized during the reporting period on marketable securities still held at the reporting date $ 48,365 $ 24,576 $ 38,159 $ 38,433 The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. • Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value measurement. The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The Company’s U.S. Treasury Bills are considered held-to-maturity securities and are valued at amortized cost. Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income from U. S. Treasury Bills and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis. Proceeds from the sale and redemption of marketable securities amounted to $ 6,673,508 for the first half of 2026, with realized gains of $ 27,948 recognized on these sales. Proceeds from the sale and redemption of marketable securities amounted to $ 7,301,264 for the first half of 2025, with realized losses of $ 1,507 recognized on those sales. 12 of 23 The following tables summarize the Company’s investments: June 30, 2026 (unaudited) Unrealized Cost Fair Value Gain Equity securities: Equity and other mutual funds $ 750,441 $ 853,443 $ 103,002 Other short-term investments: U.S. Treasury Bills (original maturities > 3 months) 6,349,613 6,349,613 --- Total marketable securities $ 7,100,054 $ 7,203,056 $ 103,002 December 31, 2025 (audited) Unreali zed Cost Fair Value Gain Equity securities: Equity and other mutual funds $ 713,120 $ 777,963 $ 64,843 Other short-term investments: U.S. Treasury Bills (original maturities > 3 months) 6,544,683 6,544,683 --- Total marketable securities $ 7,257,803 $ 7,322,646 $ 64,843 11. Inventories June 30, December 31, 2026 2025 (unaudited) (audited) Inventories consist of the following: Raw materials $ 485,423 $ 442,993 Work in process 45,605 5,505 Finished products 648,422 1,059,265 Total inventories $ 1,179,450 $ 1,507,763 Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at June 30, 2026 and December 31, 2025 are stated net of a reserve of $ 24,000 and $ 32,000 , respectively, for slow moving and obsolete inventory. 12. Income Taxes The Company’s tax provision is based on its estimated annual effective tax rate. We continue to fully recognize our tax benefits, and as of June 30, 2026 and December 31, 2025, we did not have any unrecognized tax benefits. Our provision for income taxes for the six months ended June 30, 2026 and 2025 comprises the following: 13 of 23 Three months ended Six months ended June 30, June 30, 2026 2025 2026 2025 Provision for (benefit from) federal income taxes - current $ 295,157 $ ( 51,536 ) $ 385,344 $ 56,324 Provision for state income taxes - current --- --- 813 813 (Benefit from) provision for federal income taxes - deferred ( 106,131 ) 215,312 17,105 253,703 Total provision for income taxes $ 189,026 $ 163,776 $ 403,262 $ 310,840 13. Defined Contribution Plan The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4 % of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions immediately. The Company can also elect to make discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows: 20 % after two years of employment, and 20 % for each year of employment thereafter until the employee becomes fully vested after six years of employment. The Company accrued $ 40,000 in discretionary contributions to the DC Plan for the six months ended June 30, 2026 and $ 57,500 for the six months ended June 30, 2025. In the first half of 2026, there were no discretionary contributions made to the DC Plan. This was due to the Company’s Board of Directors electing not to fund a discretionary contribution for the year ended December 31, 2025, based on reduced sales and earnings. In the first half of 2025, the Company made discretionary contributions of $ 115,000 to the DC Plan. This payment represented the Company’s 2024 accrued discretionary contributions. 14. Other Information Accrued Expenses: June 30, December 31, 2026 (unaudited) 2025 (audited) Bonuses $ 135,926 $ 182,383 Distribution fees 473,344 463,331 Payroll and related expenses 125,492 90,151 Reserve for outdated material 202,222 194,947 Company 401(k) contribution 40,000 --- Audit fee 47,793 72,708 Annual report expenses 40,583 80,387 Sales rebates 97,484 55,983 Waste Disposal Costs 23,208 13,765 Insurance 17,856 --- Other 15,425 11,293 Total accrued expenses $ 1,219,333 $ 1,164,948 14 of 23 15. Recent Accounting Pronouncements In July 2025, the FASB issued ASU 2025-05, which provides (1) all entities with a practical expedient and (2) entities other than public business entities with an accounting policy election when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, Revenue from Contracts with Customers. The practical expedient allows an entity to assume that, when estimating expected credit losses, current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. The accounting policy election permits nonpublic entities that elect the practical expedient to also consider collection activity occurring after the balance sheet date when estimating expected credit losses. The standard is effective for fiscal years beginning after December 15, 2025, and for interim periods within those annual reporting periods. Early adoption is permitted. The Company adopted ASU 2025-05 for the year ended December 31, 2025. The adoption did not have a material impact on its financial condition, results of operations or cash flows. On November 4, 2024, the FASB issued ASU 2024-03 “ Disaggregation of Income Statement Expenses ” (“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01, clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027. In December 2023, the FASB issued ASU 2023-09 “ Income Taxes- Improvements to Income Tax Disclosures. ” This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024. On January 1, 2025, the Company implemented this standard and applied the guidance under the new standard to include additional disclosures in this Form 10-K for the year ended December 31, 2025. 16. Concentrations of Credit Risk Customer Concentration : Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable has been reduced. During the three months ended June 30, 2026, the Company’s largest cosmetic ingredient distributors and three of its pharmaceutical distributors collectively accounted for 79 % of the Company’s gross sales, and 85 % of its outstanding accounts receivable at June 30, 2026. During the three months ended June 30, 2025, the same cosmetic ingredient distributor and three pharmaceutical distributors collectively accounted for 79 % of the Company’s gross sales and 86 % of its outstanding accounts receivable at June 30, 2025. During the six months ended June 30, 2026, the Company’s largest cosmetic ingredient distributors, along with three of its pharmaceutical distributors collectively accounted for 76 % of the Company’s gross sales and 85 % of its outstanding accounts receivable at June 30, 2026. During the six-month period ended June 30, 2025, the same cosmetic ingredient distributor and three pharmaceutical distributors collectively accounted for 73 % of the Company’s gross sales and 86 % of its outstanding accounts receivable at June 30, 2025. 15 of 23 17. Supplier Concentration Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals that are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times. During the first half of 2026 and 2025, the Company had three major raw material suppliers that collectively accounted for approximately 83 % and 85 %, respectively, of the raw material purchases made by the Company. For the three months ended June 30, 2026 and 2025, the Company had three major raw material suppliers that collectively accounted for approximately 83 % and 92 %, respectively, of the raw material purchases made by the Company. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream. 18. Related-Party Transactions For the three- and- six-month periods ended June 30, 2026, the Company made payments of $ 4,399 and $ 14,231 , respectively, to the accounting firm PKF O’Connor Davies ( “PKF”) for accounting and tax services. Lawrence Maietta, a former partner at PKF, is a director of the Company and is currently serving as a senior consultant at PKF. For the three-month period ended June 30, 2025, there were no payments made to PKF. For the six-month period ended June 30, 2025, the Company made payments of $ 4,000 to PKF for accounting and tax services. 19. Earnings Per Share Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period, increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued. Per share basic and diluted earnings amounted to $ 0.16 and $ 0.14 for the three months ended June 30, 2026 and 2025, respectively, and $ 0.34 and $ 0.26 for the six months ended June 30, 2026 and 2025, respectively. 20. Dividends On January 26, 2026, the Company’s Board of Directors declared a cash dividend of $ 0.25 per share, which was paid on February 17, 2026 , to all holders of record as of February 9, 2026 . During the first quarter of 2026, the Company declared a total of $ 1,148,580 in dividends, of which $ 1,148,536 was paid. The balance of $ 44 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares or are pending escheatment. In addition, during the quarter ended March 31, 2026, the Company made payments of $ 1,356 in dividends in arrears to shareholders who had either converted their Guardian Chemical shares to United-Guardian, Inc. shares or whose shares had been escheated. On January 27, 2025 the Company’s Board of Directors declared a cash dividend of $ 0.35 per share, which was paid on February 18, 2025 to all holders of record as of February 10, 2025 . During the first half of 2025, the Company declared a total of $ 1,608,012 in dividends, of which $ 1,607,893 was paid. The balance of $ 119 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. In addition, during the second quarter of 2025, the Company made payments of $ 10,290 in dividends in arrears to shareholders who had either converted their Guardian Chemical shares to United-Guardian, Inc. shares or whose shares had been escheated. 21. Subsequent Events On July 14, 2026, the Company’s Board of Directors declared a cash dividend of $ 0.30 per share, which was paid on August 4, 2026 , to all holders of record as of July 28, 2026 . Dividends totaling $ 1,378,267 were paid on August 4, 2026, leaving a balance of $ 29 that was not paid. This $ 29 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. 16 of 23 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. FORWARD-LOOKING STATEMENTS You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results. EXECUTIVE OVERVIEW Through our Guardian Laboratories division, we specialize in manufacturing cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. With a long-standing reputation for delivering high-quality specialty products, we are committed to serving diverse markets with innovative solutions. In January 2026, we entered into a new distribution agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for the distribution of our new Natrajel ® line of sexual wellness ingredients in the United States, Canada, and Mexico, and the distribution of Lubrajel ® and Natrajel products in France. The new agreement provides an opportunity to grow the French market, which is known for innovation in personal care products. In the second quarter of 2026, there was a nominal amount of sales of our sexual wellness products. Although sales of this product line are just beginning to commence, we are optimistic as to the potential this market offers. The sexual wellness segment is expected to grow at a higher compound annual growth rate (“CAGR”) than other segments such as skin care, personal care and cosmetics. With a refined product portfolio and strategic partnerships, we are well-positioned for future growth, leveraging our expertise in specialty ingredients to capitalize on emerging market opportunities. In 2025, we launched an insurance payer outreach program with the goal of having Renacidin, our most important pharmaceutical product, included on additional drug formularies. As a result of this effort, we have received approval from two major Pharmacy Benefit Managers (“PBM’s”) for inclusion on their formularies beginning in 2026. One of these PBM’s began including Renacidin on its formulary effective June 1, 2026, and the other on July 1, 2026. While we will continue our insurance payer outreach as we move through 2026, we will also introduce a new outreach program with the focus on increasing awareness among healthcare professionals to grow the market for Renacidin. CRITICAL ACCOUNTING POLICIES As disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in conformity with US GAAP. The preparation of those financial statements required us to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues, and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. Our most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2025, there have been no significant changes to the assumptions and estimates related to those critical accounting policies. 17 of 23 The following discussion and analysis cover material changes in our financial condition since the year ended December 31, 2025, and a comparison of the results of operations for the three and six months ended June 30, 2026 and June 30, 2025. This discussion and analysis should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2025. All references in this quarterly report to “sales” or “Sales” shall mean Net Sales unless specified otherwise. In accordance with ASU-2016-13, we recognize an allowance for credit losses for financial assets carried at amortized cost to present the net amount expected to be collected as of the balance sheet date. Such allowance is based on the credit losses expected to arise over the life of the asset. RESULTS OF OPERATIONS Net Sales Net sales for the second quarter of 2026 increased by $270,042 (10%) when compared with the same period in 2025. Net sales for the first half of 2026 increased by $661,137 (12%) as compared with the corresponding period in 2025. The increase in sales for the second quarter of 2026 and the first half of 2026 was attributable to changes in sales of the following product lines: Pharmaceuticals : Because there are fees, rebates and allowances associated with sales of our two pharmaceutical products, Renacidin and Clorpactin ® WCS-90, discussion of pharmaceutical sales includes references to both gross sales (before fees, rebates, and allowances) and net sales (after fees, rebates, and allowances). Gross sales of our pharmaceutical products for the three-month period ended June 30, 2026 increased by $4,904 (less than 1%) compared with the corresponding period in 2025. The increase in gross sales was primarily due to an increase of $22,821 (1%) in gross sales of Renacidin combined with a decrease of $17,917 (11%) in gross sales of the Company’s other pharmaceutical product, Clorpactin WCS-90. The decrease in Clorpactin WCS-90 sales was due to the timing of customer orders. For the six-month period ended June 30, 2026, gross pharmaceutical sales increased by $331,107 (11%) compared with the corresponding period in 2025. This increase was primarily due to an increase in gross sales of Renacidin of $312,752 (10%) combined with an increase in gross sales of Clorpactin WCS-90 of $18,355 (6%). Net sales of our pharmaceutical products for the three- and six-month periods ended June 30, 2026 saw a similar pattern, with net sales increasing by $16,663 (1%) and $292,173 (11%), respectively. With the benefits from our insurance payer outreach program starting to take shape, we are hopeful that the new formulary wins combined with the focus on increasing awareness of Renacidin among healthcare professionals, will create increased demand for Renacidin in the future. Typically, any differences between the change in net sales compared with the change in gross sales for these products is due to a combination of the change in gross sales of those products combined with changes in pharmaceutical sales allowances related to these products. Typically, these allowances have a direct relationship to the sales of the Company’s pharmaceutical products. Cosmetic and Sexual Wellness ingredients : (a) Second quarter sales : For the second quarter of 2026, sales of our cosmetic and sexual wellness ingredients increased by $390,150 (44%) when compared with the second quarter of 2025. The increase was due primarily to a net increase of $286,282 (38%) in sales to our largest cosmetic distributor, ASI, when compared with the second quarter of 2025. This increase was primarily due to ASI resuming regular purchases of the Company’s products after experiencing an overstock situation in 2025. 18 of 23 Second quarter sales to the Company’s four other distributors, as well as two direct customers, increased by a net of $103,868 (77%) compared with the second quarter of 2025. The increase was attributable to sales increases of $122,216 (161%) to the Company’s distributors in the U.K. and France and two direct customers. These increases were partially offset by a decrease in sales of $18,348 (31%) to the Company’s distributors in Switzerland, Korea and Italy. (b) Six-month sales : For the first half of 2026 sales of our cosmetic and sexual wellness ingredients increased by $536,417 (34%) when compared with the corresponding period in 2025. This increase was primarily due to a net increase in sales to ASI of $489,381 (40%) when compared with the first half of 2025. The increase in sales during the first half of 2026 was primarily due to same reason discussed above regarding ASI returning to normal ordering patterns after dealing with an overstock situation during 2025. Six-month sales to the Company’s four other distributors, as well as two direct customers, increased by a net of $47,036 (12%), compared with the same period in 2025. Sales to the Company’s distributors in the United Kingdom, Korea, France and Switzerland increased by $94,619 (30%), while sales to the Company’s distributor in Italy and two direct customers decreased by a combined $47,583 (69%). Medical lubricants : For the three-month period ended June 30, 2026, sales of our medical lubricants decreased by $136,771 (28%) compared with the same period in 2025. The decrease in sales for the three-month period was primarily due to a decrease in orders from the Company’s largest customer in India. For the six-month period ended June 30, 2026, sales of our medical lubricants decreased by $167,453 (15%) compared with the same period in 2025. The decrease in sales for the six-month period was primarily due to the same reason above, and was related to reduced orders from our largest customer in India. Cost of Sales Cost of sales as a percentage of net sales increased slightly to 50% in the second quarter of 2026 from 47% in the second quarter of 2025. For the first six months of 2026, cost of sales as a percentage of sales increased to 50% compared with 46% for the first six months of 2025. The increase in both periods was primarily due to the units sold in 2026 carrying an increased overhead cost resulting from lower unit production levels in 2025. As a result, these units carried a higher overhead cost, and when these units were sold in the current year the cost of sales increased. Operating Expenses Operating expenses, consisting of selling and general and administrative expenses, decreased by $26,768 (4%) for the three-months ended June 30, 2026, compared with the same period in 2025. For the six-month period ended June 30, 2026, operating expenses increased by $7,460 (less than 1%), compared with the same period in 2025. The decrease in the three-month period was primarily due to decreases in sales and marketing travel, consulting fees, and the Company’s 401K Plan discretionary contribution. Research and Development Expenses Research and development expenses increased by $16,527 (15%) for the three-month period ended June 30, 2026, and $17,154 (8%) for the six-month period ended June 30, 2026, compared with the same periods in 2025. The increase in both periods was primarily due to increases in payroll and payroll-related expenses. Investment Income Investment income decreased by $128 (less than 1%) and $15,001 (10%), respectively, for the three-and six-month periods of 2026 compared with the same periods in 2025. The decrease was primarily due to decreases in interest rates in 2026 compared to 2025. 19 of 23 Net gain on Marketable Securities The net gain on marketable securities increased by $23,789 and $29,181, respectively, for the three-and six-month periods ended June 30, 2026, compared to the same periods in 2025. These increases were due to 1) increases in the market value of these securities based on market conditions, and 2) the recognition of a gain on the sale of equity mutual funds in the first quarter of 2026, compared to a loss on those sales in the first quarter of 2025. The Company’s management and Board of Directors are continuing to closely monitor our investment portfolio and have made and will continue to make any changes they believe may be necessary or appropriate to minimize the future impact on our financial position that the volatility of the global financial markets may have. Settlement Income Included in net income for the three- and six-month periods ended June 30, 2026, is a monetary settlement paid to us by the contract manufacturer (“CM”) of our pharmaceutical product Renacidin. The settlement relates to the unexpected shutdown of the CM’s facility during the latter part of 2023 and in the beginning of 2024. During this time, we were unable to fill complete orders of Renacidin. On October 27, 2023, we notified the CM of our intention to file a claim for damages in connection with the CM’s breach of our supply contract with the CM, and we requested compensation for the loss of sales during the shutdown period. The settlement, which was agreed upon by both parties, called for the CM to supply us with a specified volume of product at no cost. The majority of the product covered by this agreement was received at our facility in March of 2026 and was valued at $303,133. During the second quarter of 2026, the remaining product covered by the agreement was received and was valued at $36,360. As of the date of this report, the CM has fulfilled their full obligation under the agreement, and there are no additional monies owed to the Company. Provision for Income Taxes The Company's effective income tax rate was 21% for the first half and second quarter of both 2026 and 2025. The Company’s tax rate is expected to remain at 21% for the current fiscal year. LIQUIDITY AND CAPITAL RESOURCES Working capital increased from $10,532,076 at December 31, 2025 to $10,977,452 at June 30, 2026, an increase of $445,376. The current ratio remained the same at 7.3 to 1 at both June 30, 2026 and December 31, 2025. The increase in working capital was primarily due to an increase in cash and cash equivalents. The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months. The Company intends to utilize its available cash and assets primarily for its continued organic growth and potential future strategic transactions, as well as to mitigate the potential impact of inflation on the Company's business. The Company generated cash from operations of $2,124,531 and $625,323 for the first half of 2026 and 2025, respectively. The increase was primarily due to an increase in net income, combined with decreases in inventories and prepaid income taxes. Net cash provided by investing activities was $165,002 and $ 885,686, respectively, for the first half of 2026 and 2025. The decrease was due to some proceeds from the sale of marketable securities from the first half of 2025 not being reinvested. For the six-month period ended June 30, 2026, these proceeds were primarily reinvested in U.S. Treasury Bills. Net cash used in financing activities was $1,149,892 and $1,618,183 for the first half of 2026 and 2025, respectively. The decrease in cash used in financing activities was primarily due to the payment of lower dividends in the first half of 2026 compared to the same period in 2025. We declared dividends of $0.25 per share in the first half of 2026, compared to $0.35 per share in the first half of 2025. The Company expects to continue to use its cash to make dividend payments, purchase marketable securities, and take advantage of growth opportunities that are in the best interest of the Company and its shareholders. 20 of 23 OFF BALANCE-SHEET ARRANGEMENTS The Company has no off-balance sheet transactions that have, or are reasonably likely to have, a current or future impact on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. CONTRACTUAL OBLIGATIONS AND COMMITMENTS The information to be reported under this item is not required of smaller reporting companies. Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. The information to be reported under this item is not required of smaller reporting companies. Item 4. CONTROLS AND PROCEDURES. (a) DISCLOSURE CONTROLS AND PROCEDURES The Company’s management, including its Principal Executive Officer and Chief Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Chief Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures. (b) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING The Company's Principal Executive Officer and Chief Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation. PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS NONE ITEM 1A. RISK FACTORS The information to be reported under this item is not required of smaller reporting companies. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS NONE 21 of 23 ITEM 3. DEFAULTS UPON SENIOR SECURITIES NONE ITEM 4. MINE SAFETY DISCLOSURESa NONE ITEM 5. OTHER INFORMATION NONE ITEM 6. EXHIBITS 31.1 * Certification of Donna Vigilante, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 * Certification of Andrea Young, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32 * Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS* Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document. 101.SCH* Inline XBRL Taxonomy Extension Schema Document. 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104* Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101.1). * Filed herewith 22 of 23 SIGNATURES In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNITED-GUARDIAN, INC. (Registrant) Date: August 5, 2026 By: /S/ DONNA VIGILANTE Donna Vigilante President By: /S/ ANDREA YOUNG Andrea Young Chief Financial Officer 23 of 23